The Biomedical Advanced Research and Development Authority granted Basilea Pharmaceutica a six-year contract worth as much as $89 million to support development of its novel monosulfactam antibiotic BAL30072. The drug, which is under development for severe infections, was chosen because of its broad coverage against multidrug-resistant Gram-negative pathogens. Basilea initially will get $17 million over 22 months.

Full Story:
RTT News

Related Summaries